Compare APA & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | APA | ABVX |
|---|---|---|
| Founded | 1954 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.5B |
| IPO Year | 2021 | N/A |
| Metric | APA | ABVX |
|---|---|---|
| Price | $31.62 | $113.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 20 | 12 |
| Target Price | $25.21 | ★ $128.42 |
| AVG Volume (30 Days) | ★ 6.4M | 688.8K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 75.77 | N/A |
| EPS | ★ 3.99 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.33 | $0.22 |
| P/E Ratio | $7.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.58 | $4.77 |
| 52 Week High | $30.31 | $148.83 |
| Indicator | APA | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 70.31 | 40.38 |
| Support Level | $22.73 | $107.99 |
| Resistance Level | N/A | $131.27 |
| Average True Range (ATR) | 1.28 | 4.89 |
| MACD | 0.23 | -0.83 |
| Stochastic Oscillator | 81.11 | 9.65 |
APA Corp is an independent exploration and production company. It develops, and produces crude oil, natural gas, and natural gas liquids. The Company's business has oil and gas operations in three geographic areas: the United States (U.S.), Egypt, and offshore the U.K. in the North Sea (North Sea). APA also has active development, exploration, and appraisal operations ongoing in Suriname, as well as exploration interests in Uruguay, Alaska, and other international locations.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.